Shifting the Evolving CAR T Cell Platform into Higher Gear

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T cell therapy is a promising cancer treatment.
• Optimizing CAR T cell function, including expansion and persistence, is crucial for efficacy.
• T cell exhaustion can limit the effectiveness of CAR T cell therapies.

Purpose of the Study:

• To evaluate the impact of different chimeric antigen receptor (CAR) T cell constructs on T cell function.
• To determine if constitutive expression of 4-1BBL enhances CAR T cell anti-tumor activity.
• To assess the effect of 4-1BBL expression on T cell expansion and exhaustion.

Main Methods:

• Testing various chimeric antigen receptor (CAR) T cell designs in vitro and/or in vivo.
• Quantifying T cell expansion and tumor eradication.
• Measuring markers of T cell exhaustion.

Main Results:

• CD28-CD3ζ CAR T cells constitutively expressing 4-1BBL demonstrated enhanced T cell expansion.
• These engineered CAR T cells led to improved tumor eradication.
• The expression of 4-1BBL reduced T cell exhaustion.

Conclusions:

• Constitutive 4-1BBL expression in CD28-CD3ζ CAR T cells promotes robust anti-tumor responses.
• This strategy offers a potential method to overcome T cell exhaustion in CAR T cell therapy.
• The findings support the development of improved CAR T cell therapies for cancer patients.